文献速递肝胆胰外科围术期管理与 ERAS

机器人与开腹胰十二指肠切除术联合门肠系膜静脉切除的30天死亡率与并发症比较:系统综述与meta分析

Comparative 30-day mortality and complications in robotic vs. open pancreaticoduodenectomy with portal-mesenteric vein resection: a systematic review and meta-analysis.
PubMed 文献 · Surg Endosc · 2025-08-07

该系统综述与meta分析纳入4项观察性研究共288例胰腺导管腺癌患者,比较机器人胰十二指肠切除术联合门肠系膜静脉切除(RPD+PMVR,n=69)与开腹手术联合门肠系膜静脉切除(OPD+PMVR,n=219)的围手术期结局。结果显示两组30天死亡率、主要并发症、术后胰瘘、胃排空延迟及胰腺切除术后出血均无显著差异,但RPD+PMVR组住院时间显著缩短(平均差-4.76天,95%CI -7.85至-1.67,p=0.003)。

要点

  • RPD+PMVR与OPD+PMVR在30天死亡率和主要并发症方面无显著差异。
  • RPD+PMVR组住院时间较OPD+PMVR组平均缩短4.76天(95%CI -7.85至-1.67)。
  • 术后胰瘘、胃排空延迟和胰腺切除术后出血两组间无显著差异。

核心结论

  • RPD+PMVR与OPD+PMVR在安全性和有效性方面相当,且RPD+PMVR可缩短住院时间。

研究设计与样本

  • 系统综述与meta分析,检索PubMed、Google Scholar、EMBASE和Cochrane Central Register of Controlled Trials从2010年1月至2024年9月发表的观察性研究。
  • 共纳入4项研究,288例胰腺导管腺癌患者,其中RPD+PMVR组69例,OPD+PMVR组219例。
  • 采用随机效应模型计算合并估计值。

主要发现

  • 30天死亡率:RPD+PMVR组6.3% vs OPD+PMVR组5.6%,OR 1.29(95%CI 0.41-4.03),p=0.66,I2=0%。
  • 主要并发症:RPD+PMVR组14.5% vs OPD+PMVR组21%,OR 0.66(95%CI 0.32-1.39),p=0.27,I2=0%。
  • 胰腺切除术后出血:RPD+PMVR组19% vs OPD+PMVR组8.9%,OR 2.44(95%CI 0.52-11.5),p=0.26,I2=45%。
  • 术后胰瘘:RPD+PMVR组4.8% vs OPD+PMVR组7.04%,OR 0.87(95%CI 0.25-2.94),p=0.82,I2=0%。
  • 胃排空延迟:RPD+PMVR组23.8% vs OPD+PMVR组14.6%,OR 1.81(95%CI 0.88-3.72),p=0.11,I2=0%。

临床怎么用

  • 在具备机器人手术技术和经验的中心,RPD+PMVR可作为PDAC伴血管侵犯患者的可行选择,安全性与开腹手术相当且可能缩短住院时间。

局限性

  • 纳入研究均为观察性研究,可能存在选择偏倚。
  • 样本量较小(共288例),RPD+PMVR组仅69例。
  • 纳入研究数量少(4项),证据等级有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Portal-mesenteric vein resection (PMVR) is often necessary for pancreatic ductal adenocarcinoma (PDAC) with vascular invasion. While open pancreaticoduodenectomy (OPD) is the standard approach, robotic pancreaticoduodenectomy (RPD) offers a minimally invasive alternative with potential benefits but faces challenges related to technical complexity and safety. This meta-analysis compares perioperative outcomes of RPD with PMVR versus OPD with PMVR in PDAC. METHODS: A search of PubMed, Google Scholar, EMBASE, and the Cochrane Central Register of Controlled Trials identified observational studies published from January 2010 to September 2024. Studies included compared RPD and OPD with PMVR in PDAC, reporting 30-day mortality, major complications (Clavien-Dindo classification), and complications such as postoperative pancreatic fistulas (POPF), delayed gastric emptying (DGE), and post-pancreatectomy hemorrhage (PPH). Pooled estimates were calculated using a random-effects model. RESULTS: Four studies involving 288 patients met inclusion criteria (RPD + PMVR: n = 69; OPD + PMVR: n = 219). Thirty-day mortality (6.3% vs 5.6%, OR: 1.29, 95% CI 0.41-4.03, p = 0.66, I2 = 0%), major complications (14.5% vs 21%, OR: 0.66, 95%CI 0.32-1.39, p = 0.27, I2 = 0%), PPH (19% vs 8.9%, OR: 2.44, 95%CI 0.52-11.5, p = 0.26, I2 = 45%), POPF (4.8% vs 7.04%, OR: 0.87, 95% CI 0.25-2.94, p = 0.82, I2 = 0%), and DGE (23.8% vs 14.6%, OR: 1.81, 95% CI 0.88-3.72, p = 0.11, I2 = 0%) were comparable between the RPD + PMVR and OPD + PMVR groups. However, RPD + PMVR was associated with a significantly shorter hospital length of stay (LOS) (mean difference: -4.76 days, 95% CI - 7.85 to - 1.67, p = 0.003, I2 = 34%). CONCLUSIONS: RPD + PMVR is comparable to OPD + PMVR in terms of safety and efficacy, with the added benefit of reduced hospital LOS.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Mejia A, Vivian E, Shah J, et al. Comparative 30-day mortality and complications in robotic vs. open pancreaticoduodenectomy with portal-mesenteric vein resection: a systematic review and meta-analysis. Surg Endosc. 2025. PMID: 40775468. doi:10.1007/s00464-025-12002-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。